Skip to main content
. 2017 Oct 31;15(1):545–551. doi: 10.3892/ol.2017.7302

Table II.

Association between PHD3 and HIF2α expression and clinicopathological parameters in HCC (detected by immunohistochemistry).

PHD3 HIF2α


Variable + +% χ2 P-value + +% χ2 P-value
Age, years
  <50 44 20 68.8 0.525 0.469 26 38 40.6 0.002 0.960
  ≥50 12   8 60.0 8 12 40.0
Sex
  Male 48 22 68.6 0.686 0.408 28 42 40.0 0.040 0.842
  Female   8   6 57.1 6   8 42.9
Tumor size, cm
  ≤5 42 10 80.8 12.216 <0.001b 26 26 50.0 2.844 0.092
  >5 14 18 43.8 8 24 25.0
AFP
  <400 32 20 61.5 1.615 0.204 24 28 46.2 1.826 0.177
  ≥400 24   8 75.0 10 22 31.2
TNM stage
  I–II 38 22 63.3 1.050 0.306 26 34 43.3 0.712 0.399
  III–IV 18   6 75.0 8 16 33.3
Edmonson
  I–II 38   8 82.6 11.629 0.001a 22 24 47.8 2.280 0.131
  III–IV 18 20 47.4 12 26 31.6
Portal vein tumor thrombus
  No 46 26 63.9 1.750 0.186 30 42 41.7 0.296 0.586
  Yes 10   2 83.3 4 8 33.3

+, Positive; -, Negative; +%, Positive rate

a

P<0.01

b

P<0.001. PHD3, prolyl hydroxylase 3; HIF2α, hypoxia-inducible factor 2α; HCC, hepatocellular carcinoma; TNM, tumor, node and metastasis; AFP, α-fetoprotein.